The retinoid X receptor binding to the thyroid hormone receptor: Relationship with cofactor binding and transcriptional activity

Journal of Molecular Endocrinology

Volumn 42, Issue 5, 2009, Pages 415-428

  Tagami, Tetsuya ^a   Yamamoto, Hiroyuki ^a   Moriyama, Kenji ^a   Sawai, Kuniko ^a   Usui, Takeshi ^a   Shimatsu, Akira ^a   Naruse, Mitsuhide ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; HETERODIMER; MEMBRANE COFACTOR PROTEIN; NUCLEAR RECEPTOR COACTIVATOR; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN VP16; RETINOID X RECEPTOR; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR BINDING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TWO HYBRID SYSTEM; X RAY CRYSTALLOGRAPHY;

BLOTTING, WESTERN; CELL LINE; DNA; GENES, REPORTER; HUMANS; MODELS, MOLECULAR; MUTANT PROTEINS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, THYROID HORMONE; REPRESSOR PROTEINS; RETINOID X RECEPTORS; TRANSCRIPTION, GENETIC; TRIIODOTHYRONINE; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 67649373040     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-08-0153     Document Type: Article

References (52)

1. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N & DePinho RA 1997 Role for N-Cor and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387 49-55.
2. Anderson ML, Nordstorm K, Demczuk S, Harbes M & Vennstrom B 1992 Thyroid hormone alters the DNA binding properties of chicken thyroid hormone receptors a and b. Nucleic Acids Research 20 4803-4810.
3. Au-Fliegner M, Helmer E, Casanova J, Raaka BM & Samuels HH 1993 The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation. Molecular and Cellular Biology 13 5725-5737.
4. Baniahmad A, Kohne AC & Renkawitz R 1992 A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product and in the retinoic acid receptor. EMBO Journal 11 1015-1023.
5. Bannister A & Kouzarides T 1996 The CBP co-activator is a histone acetyltransferase. Nature 384 641-643.
6. Beck-Peccoz P, Chatterjee VK, Chin WW, DeGroot LJ, Jameson JL, Nakamura H, Refetoff S, Usala SJ & Weintraub BD 1994 Nomenclature of thyroid hormone receptor beta-gene mutations in resistance to thyroid hormone: consensus statement from the first workshop on thyroid hormone resistance. Journal of Clinical Endocrinology and Metabolism 78 990-993.
7. Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y & Ozato K 1998 The histone acetylase PCAF is a nuclear receptor coactivator. Genes and Development 12 1638-1651.
8. Bourguet W, Ruff M, Chambon P, Gronemeyer H & Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375 377-382.
9. 3-inducible promoters and blocks activity of the retinoic acid receptor. New Biologist 1 329-336.
10. Chen JD & Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377 454-457.
11. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y & Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimetric activation complex with P/CAF and CBP/p300. Cell 90 569-580.
12. Damm K, Thompson CC & Evans RM 1989 Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. Nature 339 593-597.
13. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ & Yamamoto KR 1998 Structure and specificity of nuclear receptor-coactivator interactions. Genes and Development 12 3343-3356.
14. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ & West BL 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 1747-1749.
15. Forman BM, Casanova J, Raaka BM, Ghysdael J & Samuels HH 1992 Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. Molecular Endocrinology 6 429-442.
16. Heery DM, Kalkhoven E, Hoare S & Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 733-736.
17. Heinzel T, Lavinsky RM, Mullen T-M, Soderstrom M, Laherty CD, Torchia J, Yang W-M, Brard G, Ngo SD, Davie JR et al. 1997 A complex containing N-CoR, mSIN3 and histone deacetylase mediates transcriptional repression. Nature 387 43-48.
18. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK et al. 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 397-404.
19. Hu X & Lazar MA 1999 The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 93-99.
20. Kitajima K, Nagaya T & Jameson JL 1995 Dominant negative and DNA-binding properties of mutant thyroid hormone receptors that are defective in homodimerization but not heterodimerization. Thyroid 5 343-353.
21. Lazar MA, Berrodin TJ & Harding HP 1991 Differential DNA binding by monomeric, homodimeric, and potentially heteromeric forms of the thyroid hormone receptor. Molecular and Cellular Biology 11 5005-5015.
22. LeDouarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P & Losson R 1995 The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO Journal 14 2020-2033.
23. Lin KH, Willingham MC, Liang C-M & Cheng S-Y 1991 Intracellular distribution of the endogenous and transfected b form of thyroid hormone nuclear receptor visualized by the use of domain-specific monoclonal antibodies. Endocrinology 128 2601-2609.
24. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839.
25. Marimuthu A, FengW, Tagami T, Nguyen H, Jameson JL, Fletterick RJ, Baxter JD & West BL 2002 TR surfaces and conformations required to bind nuclear receptor corepressor. Molecular Endocrinology 16 271-286.
26. Nagaya T & Jameson JL 1993 Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. Journal of Biological Chemistry 268 15766-15771.
27. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL & Evans RM 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSIN3 and histone deacetylase. Cell 89 373-380.
28. Nagy L, Kao H-Y, Love JD, Li C, Banayo E, Gooch JT, Chatterjee VKK, Evans RM & Schwabe JWR 1999 Mechanism of corepressor binding and release from nuclear hormone receptors. Genes and Development 13 3209-3216.
29. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK & Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferatoractivated receptor-gamma. Nature 395 137-143.
30. Perissi V, Staszewski LM, Naar AM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK et al. 1999 Molecular determinations of nuclear receptor-corepressor interaction. Genes and Development 13 3198-3208.
31. Pissios P, Trameli I, Kushner PJ & Moore DD 2000 Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Molecular Cell 6 245-253.
32. Rachez C, Suldan Z, Ward J, Chang C-P, Burakov D, Erdjument-Bromage H, Tempst P & Freedman LP 1998 A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes and Development 12 1787-1800.
33. Refetoff S, Weiss RE & Usala SJ 1993 The syndromes of resistance to thyroid hormone. Endocrine Reviews 14 348-399.
34. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H & Moras D 1995 Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378 681-689.
35. Ribeiro RCJ, Feng W, Wagner RL, Costa CHRM, Pereira AC, Apriletti JW, Fletterick RJ & Baxter JD 2001 Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. Journal of Biological Chemistry 276 14987-14995.
36. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
37. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai M-J et al. 1997 Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389 194-198.
38. Tagami T & Jameson JL 1998 Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone. Endocrinology 139 640-650.
39. Tagami T, Nakamura H, Sasaki S, Miyoshi Y & Imura H 1993 Estimation of the protein content of thyroid hormone receptor α1 and β1 in rat tissues by Western blotting. Endocrinology 132 275-279.
40. Tagami T, Madison LD, Nagaya T & Jameson JL 1997a Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Molecular and Cellular Biology 17 2642-2648.
41. Tagami T, Nakamura H, Sasaki S, Miyoshi Y & Nakao K 1997b Dimerization properties of mutant thyroid hormone β-receptors with auxiliary proteins. Journal of Endocrinology 154 523-533.
42. Tagami T, Lutz WH, Kumar R & Jameson JL 1998a The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochemical and Biophysical Research Communications 253 358-363.
43. Tagami T, Gu W, Peairs PT, West BL & Jameson JL 1998b A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators. Molecular Endocrinology 12 1888-1902.
44. Tagami T, Kopp P, Johnson W, Arseven OK & Jameson JL 1998c The thyroid hormone receptor variant a2 is a weak antagonist because it is deficient in interactions with nuclear receptor corepressor. Endocrinology 139 2535-2544.
45. Tagami T, Park Y & Jameson JL 1999 Mechanisms that mediate negative regulation of the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. Journal of Biological Chemistry 274 22345-22353.
46. Torchia J, Rose DW, Inostrova J, Kamei Y, Westin S, Glass CK & Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387 677-684.
47. Umesono K, Murakami KK, Thompson CC & Evans RM 1991 Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D receptors. Cell 65 1255-1266.
48. Wagner RL, Apriletti JW,McGrath ME,West BL, Baxter JD & Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378 690-697.
49. Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A,West BL, Baxter JD & Kushner PJ 2000 The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Molecular Endocrinology 14 1976-1985.
50. 3) binding decreases binding to DNA by T3-receptor homodimers but not receptor auxiliary protein heterodimers. Journal of Biological Chemistry 267 3565-3568.
51. 3 receptors and transcriptional corepressors. Molecular Endocrinology 11 470-480.
52. Zhang J, Zamir I & Lazar MA 1997 Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression. Molecular and Cellular Biology 17 6887-6897.